Skip to Content

Prevail Therapeutics, Inc. 

Merger

  • Date:
  • 12/16/2020
  • Company Name:
  • Prevail Therapeutics, Inc.
  • Stock Symbol:
  • PRVL
  • Company Name - Buyer:
  • Eli Lilly and Company
  • Stock Symbol - Buyer:
  • LLY
  • Status:
  • Investigating
  • Merger Announcement Date:
  • 12/15/2020

Case Finder

Locate any case using the tools below.

NEW YORK, December 16, 2020 – Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Prevail Therapeutics, Inc. (NASDAQ: PRVL) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Eli Lilly and Company (NYSE: LLY).

On December 15, 2020, Prevail announced that it had signed an agreement to be acquired by Eli Lilly for approximately $880 million.  Pursuant to the merger agreement, Prevail stockholders will receive $22.50 in cash, plus one non-tradable contingent value right (“CVR”) worth up to $4.00 per share in cash to be payed at closing, for each share of TCF common stock owned.  The deal is scheduled to close in the first quarter of 2021.

Bragar Eagel & Squire is concerned that Prevail’s board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement.  Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Prevail’s stockholders.
 
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Prevail Therapeutics. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: